Citations

Clear

7552 citation(s) found for "Ho, Matthew".

Long-Term Results of a 2-Stage Exchange Protocol for Periprosthetic Joint Infection Following Total Hip Arthroplasty in 164 Hips
Petis, Stephen M. , Abdel, Matthew P. , Perry, Kevin I. , Mabry, Tad M. , Hanssen, Arlen D. , Berry, Daniel J. , Petis, Stephen , Abdel, Matthew P , Berry, Daniel J

Mayo Clinic

Journal of Bone and Joint Surgery | January 19, 2019 | Volume: 101 | Issue: 1 | Pages: 74-84

10.2106/jbjs.17.01103 | PMID 30601418 Get It

Background: Limited data exist that show the long-term risks of reinfection and mechanical failure with a contemporary 2-stage exchange protocol for periprosthetic joint infection following total hip arthroplasty. The purpose of this study was to determine the long-term reinfection and mechanical failure rates of 2-stage exchange for periprosthetic joint infection after total hip arthroplasty. Methods: We identified 164 hips (162 patients) with infection after total hip arthroplasty between 1991 and 2006 treated with a 2-stage exchange protocol with no prior treatment for periprosthetic joint infection. With regard to Musculoskeletal Infection Society diagnostic criteria, at least 1 major criterion or 4 of 6 minor criteria were fulfilled in 129 hips (79%). The cumulative incidence with a competing risk of death was calculated for reinfection, aseptic revisions, and all-cause revisions. The risk factors for reinfection were evaluated using Cox proportional hazards regression. Harris hip scores were calculated. The mean age at the time of spacer insertion was 68 years, and 35% of the patients were female. Excluding the patients with <2 years of follow-up, the mean follow-up was 12 years (range, 2 to 21 years). Results: The cumulative incidence of recurrence of infection was 10% at 1 year, 14% at 5 years, and 15% at 10 and 15 years. Seventeen patients (11%) used chronic antibiotic suppression (>6 months), with 7 (41%) of these having recurrent infection at the time of the latest follow-up. Use of chronic antibiotic suppression was the only predictive factor for reinfection (hazard ratio, 4.5 [95% confidence interval (CI), 1.9 to 10.9]; p = 0.001). The cumulative incidence of aseptic femoral and acetabular revisions was 2.6% at 5 years and 3.3% at 10 and 15 years. The cumulative incidence of all-cause revisions was 15% at 5 years and 16% at 10 and 15 years. Dislocation was the most common complication, with 28 dislocations occurring in 20 patients (12%). The mean Harris hip score improved from 52 points prior to spacer insertion to 70 points at 15 years after reimplantation (p < 0.01). Conclusions: The rate of recurrence of infection of 15% for up to 15 years after total hip arthroplasty was similar to previous shorter-term reports of 2-stage exchange for periprosthetic joint infection. Surgeons should anticipate mitigating instability after reimplantation. Implant survivorship free of aseptic loosening and clinical outcomes were preserved for the long term. The role of chronic antibiotic suppression in the long-term treatment of periprosthetic joint infection requires further investigation. Level of Evidence: Therapeutic Level IV . See Instructions for Authors for a complete description of levels of evidence.
A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403
Stock, Wendy , Luger, Selina M. , Yin, Jun , Mullighan, Charles G. , Fulton, Noreen, Laumann, Kristina, Malnassy, Greg, Paietta, Elisabeth , Parker, Edy, Geyer, Susan, Mrózek, Krzysztof , Bloomfield, Clara D. , Sanford, Ben L. , Marcucci, Guido , Liedtke, Michaela , Claxton, David F. , Bogart, Jeffrey A. , Grecula, J.C., Appelbaum, Frederick R. , Litzow, Mark R. , Tallman, Martin S. , Stone, Richard M. , Mullighan, Charles G , Claxton, David F , Stock, Wendy , Advani, Anjali S. , Harvey, Richard C. , Willman, Cheryl L. , Foster, Matthew C , Erba, Harry Paul , Larson, Richard A.

Mayo Clinic

Blood | January 18, 2019 | Volume: 133 | Issue: 14 | Pages: 1548-1559

10.1182/blood-2018-10-881961 | PMID 30658992 Get It

Abstract Retrospective studies have suggested that older adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL) have better survival rates when treated using a pediatric ALL regimen administered by pediatric treatment teams. To address the feasibility and efficacy of using a pediatric treatment regimen for AYA patients with newly diagnosed ALL administered by adult treatment teams, we performed a prospective study, CALGB 10403, with doses and schedule identical to those in the Children's Oncology Group study AALL0232. From 2007 to 2012, 318 patients were enrolled; 295 were eligible and evaluable for response. Median age was 24 years (range, 17-39 years). Use of the pediatric regimen was safe; overall treatment-related mortality was 3%, and there were only 2 postremission deaths. Median event-free survival (EFS) was 78.1 months (95% confidence interval [CI], 41.8 to not reached), more than double the historical control of 30 months (95% CI, 22-38 months); 3-year EFS was 59% (95% CI, 54%-65%). Median overall survival (OS) was not reached. Estimated 3-year OS was 73% (95% CI, 68%-78%). Pretreatment risk factors associated with worse treatment outcomes included obesity and presence of the Philadelphia-like gene expression signature. Use of a pediatric regimen for AYAs with ALL up to age 40 years was feasible and effective, resulting in improved survival rates compared with historical controls. CALGB 10403 can be considered a new treatment standard upon which to build for improving survival for AYAs with ALL. This trial was registered at www.clinicaltrials.gov as #NCT00558519.
Intralesional Collagenase Clostridium histolyticum Causes Meaningful Improvement in Men with Peyronie's Disease: Results of a Multi-Institutional Analysis
Hellstrom, Wayne J.G. , Nguyen, Hoang Minh Tue, Alzweri, Laith , Chung, Amanda , Tapscott, Ashley, Ziegelmann, Matthew , Trost, Landon , Gelbard, Martin K. , Nguyen, Hoang Minh Tue, Virasoro, Ramón

Mayo Clinic

Journal of Urology | January 18, 2019 | Volume: 201 | Issue: 4 | Pages: 777-782

10.1097/ju.0000000000000032 | PMID 30672843 Get It

Long‐term olfaction outcomes in transnasal endoscopic skull‐base surgery: a prospective cohort study comparing electrocautery and cold knife upper septal limb incision techniques
Puccinelli, Cassandra L., Yin, Linda X. , O’Brien, Erin K. , Abel, Kathryn M. Van , Janus, Jeffrey R. , Stokken, Janalee K., Stokken, Janalee K. , Choby, Garret W, Van Abel, Kathryn M , O'Brien, Erin K , Yin, Linda X , Carlson, Matthew L , Gompel, Jamie J. Van , Choby, Garret

Mayo Clinic

International Forum of Allergy & Rhinology | January 18, 2019 | Volume: 9 | Issue: 5 | Pages: 493-500

10.1002/alr.22291 | PMID 30657649 Get It

BackgroundOlfactory nerve fibers are at risk of injury during transnasal endoscopic skull‐base approaches. Olfactory outcomes for various techniques have not been thoroughly investigated. This study aims to report long‐term olfactory outcomes when a cold knife upper septal limb incision technique is used compared to monopolar cautery.MethodsA prospective cohort study was performed at a tertiary referral center. Adult patients undergoing endoscopic approaches with septal incisions were randomized to cold knife or monopolar cautery groups. Patient demographics, clinical history, surgical data, and outcomes were collected. Preoperative, 3‐month, and 12‐month postoperative scores on the University of Pennsylvania Smell Inventory Test (UPSIT) and 22‐item Sino‐Nasal Outcome Test (SNOT‐22) were measured. Fisher's exact tests were performed for categorical variables and t tests were performed for continuous variables.ResultsTwenty‐two (22) patients (10 cold knife, 12 cautery) were enrolled between March 2016 and August 2017. The average age ± standard deviation was 50.2 ± 14.0 years (p = 0.59), 54% (p = 0.69) were female, and the primary pathology was pituitary adenoma (73%, p = 1.00). Preoperative, 3‐month, and 12‐month postoperative UPSIT scores were similar between the cold knife and cautery groups (32.8 vs 32.4, p = 0.80; 33.1 vs 33.0, p = 0.96; 33.6 vs 33.3, p = 0.84). On the “sense of smell/taste” question of the SNOT‐22, there was also no difference at all time points (p > 0.22).ConclusionThere was no significant change in patient UPSIT scores 1 year after transnasal skull‐base approaches, and no short‐term or long‐term differences between cold knife and cautery upper septal limb incision techniques. Our study supports an individualized approach based on surgeon preference.
Destination Joint Spacers, Reinfection, and Antimicrobial Suppression
Valencia, Jose Carlo, Virk, Abinash , Osmon, Douglas R. , Valencia, Jose Carlo B, Abdel, Matthew P. , Razonable, Raymund R.

Mayo Clinic

Clinical Infectious Diseases | January 17, 2019 | Volume: 69 | Issue: 6 | Pages: 1056-1059

10.1093/cid/ciz062 | PMID 30689767 Get It

Abstract In this cohort of 51 patients managed with retained “destination spacers” after the resection of infected joint prostheses, the presence of preoperative sinus drainage was significantly associated with reinfection. Chronic antimicrobial suppression after destination-spacer retention did not significantly prevent reinfections.
Pharmacology of bisphosphonates
Cremers, Serge , Drake, Matthew T. , Ebetino, Frank H. , Bilezikian, John P. , Russell, R.G.G. , Russell, R Graham , Drake, Matthew T

Mayo Clinic

British Journal of Clinical Pharmacology | January 16, 2019 | Volume: 85 | Issue: 6 | Pages: 1052-1062

10.1111/bcp.13867 | PMID 30650219 Get It

The biological effects of the bisphosphonates (BPs) as inhibitors of calcification and bone resorption were first described in the late 1960s. In the 50 years that have elapsed since then, the BPs have become the leading drugs for the treatment of skeletal disorders characterized by increased bone resorption, including Paget's disease of bone, bone metastases, multiple myeloma, osteoporosis and several childhood inherited disorders. The discovery and development of the BPs as a major class of drugs for the treatment of bone diseases is a paradigm for the successful journey from “bench to bedside and back again”. Several of the leading BPs achieved “blockbuster” status as branded drugs. However, these BPs have now come to the end of their patent life, making them highly affordable. The opportunity for new clinical applications for BPs also exists in other areas of medicine such as ageing, cardiovascular disease and radiation protection. Their use as inexpensive generic medicines is therefore likely to continue for many years to come. Fifty years of research into the pharmacology of bisphosphonates have led to a fairly good understanding about how these drugs work and how they can be used safely in patients with metabolic bone diseases. However, while we seemingly know much about these drugs, a number of key aspects related to BP distribution and action remain incompletely understood. This review summarizes the existing knowledge of the (pre)clinical and translational pharmacology of BPs, and highlights areas in which understanding is lacking.
Anastrozole Aromatase Inhibitor Plasma Drug Concentration Genome‐Wide Association Study: Functional Epistatic Interaction Between SLC38A7 and ALPPL2
Dudenkov, Tanda M., Liu, Duan , Cairns, Junmei , Devarajan, Sandhya, Zhuang, Yongxian , Ingle, James N. , Buzdar, Aman U. , Kubo, Michiaki , Batzler, Anthony , Barman, Poulami , Jenkins, Gregory D. , Northfelt, Donald W. , Moreno‐Aspitia, Alvaro , Desta, Zeruesenay , Wang, Liewei , Weinshilboum, Richard M. , Reid, Joel M. , Weinshilboum, Richard M. , Ingle, J , Robson, Mark E. , Carlson, Erin E. , Goetz, Matthew P. , Kalari, Krishna R. , Liu, Duan

Mayo Clinic

Clinical Pharmacology & Therapeutics | January 16, 2019 | Volume: 106 | Issue: 1 | Pages: 219-227

10.1002/cpt.1359 | PMID 30648747 Get It

Anastrozole is a widely prescribed aromatase inhibitor for the therapy of estrogen receptor positive (ER+) breast cancer. We performed a genome‐wide association study (GWAS) for plasma anastrozole concentrations in 687 postmenopausal women with ER+ breast cancer. The top single‐nucleotide polymorphism (SNP) signal mapped across SLC38A7 (rs11648166, P = 2.3E‐08), which we showed to encode an anastrozole influx transporter. The second most significant signal (rs28845026, P = 5.4E‐08) mapped near ALPPL2 and displayed epistasis with the SLC38A7 signal. Both of these SNPs were cis expression quantitative trait loci (eQTL)s for these genes, and patients homozygous for variant genotypes for both SNPs had the highest drug concentrations, the highest SLC38A7 expression, and the lowest ALPPL2 expression. In summary, our GWAS identified a novel gene encoding an anastrozole transporter, SLC38A7, as well as epistatic interaction between SNPs in that gene and SNPs near ALPPL2 that influenced both the expression of the transporter and anastrozole plasma concentrations.
RNA‐Seq detects a SAMD12‐EXT1 fusion transcript and leads to the discovery of an EXT1 deletion in a child with multiple osteochondromas
Oliver, Gavin R. , Blackburn, Patrick R. , Ellingson, Marissa S. , Conboy, Erin , Vairo, Filippo Pinto e , Webley, Matthew, Thorland, Erik C., Ferber, Matthew J. , Hul, Els Van, Werf, Ilse M. van der, Babovic‐Vuksanovic, Dusica , Klee, Eric W. , Pinto E Vairo, Filippo, Thorland, Erik, Ferber, Matthew, Babovic-Vuksanovic, Dusica, Vairo, Filippo , Wuyts, Wim A.

Mayo Clinic

Molecular Genetics & Genomic Medicine | January 11, 2019 | Volume: 7 | Issue: 3 | Pages: No page available

10.1002/mgg3.560 | PMID 30632316 Get It

AbstractBackgroundWe describe a patient presenting with pachygyria, epilepsy, developmental delay, short stature, failure to thrive, facial dysmorphisms, and multiple osteochondromas.MethodsThe patient underwent extensive genetic testing and analysis in an attempt to diagnose the cause of his condition. Clinical testing included metaphase karyotyping, array comparative genomic hybridization, direct sequencing and multiplex ligation‐dependent probe amplification and trio‐based exome sequencing. Subsequently, research‐based whole transcriptome sequencing was conducted to determine whether it might shed light on the undiagnosed phenotype.ResultsClinical exome sequencing of patient and parent samples revealed a maternally inherited splice‐site variant in the doublecortin (DCX) gene that was classified as likely pathogenic and diagnostic of the patient's neurological phenotype. Clinical array comparative genome hybridization analysis revealed a 16p13.3 deletion that could not be linked to the patient phenotype based on affected genes. Further clinical testing to determine the cause of the patient's multiple osteochondromas was unrevealing despite extensive profiling of the most likely causative genes, EXT1 and EXT2, including mutation screening by direct sequence analysis and multiplex ligation‐dependent probe amplification. Whole transcriptome sequencing identified a SAMD12‐EXT1 fusion transcript that could have resulted from a chromosomal deletion, leading to the loss of EXT1 function. Re‐review of the clinical array comparative genomic hybridization results indicated a possible unreported mosaic deletion affecting the SAMD12 and EXT1 genes that corresponded precisely to the introns predicted to be affected by a fusion‐causing deletion. The existence of the mosaic deletion was subsequently confirmed clinically by an increased density copy number array and orthogonal methodologiesConclusionsWhile mosaic mutations and deletions of EXT1 and EXT2 have been reported in the context of multiple osteochondromas, to our knowledge, this is the first time that transcriptomics technologies have been used to diagnose a patient via fusion transcript analysis in the congenital disease setting.
Type 1 First Branchial Cleft Anomaly: Duplication of the External Auditory Canal
Carlson, Matthew L. , Archibald, David, Cofer, Shelagh A. , Archibald, David J.

Mayo Clinic

Ear, Nose & Throat Journal | January 10, 2019 | Volume: 90 | Issue: 7 | Pages: 302-303

10.1177/014556131109000705 | PMID 21792796 Get It